| Jeffrey Paul Rosenbluth, MD | |
|
50 N Medical Dr, Salt Lake City, UT 84132-0001 | |
| (801) 581-2267 | |
| Not Available |
| Full Name | Jeffrey Paul Rosenbluth |
|---|---|
| Gender | Male |
| Speciality | Physical Medicine And Rehabilitation |
| Experience | 28 Years |
| Location | 50 N Medical Dr, Salt Lake City, Utah |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1578653192 | NPI | - | NPPES |
| 250013156 | Other | UT | RAILROAD MEDICARE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208100000X | Physical Medicine & Rehabilitation | 4936758-1205 (Utah) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Of Utah Hospitals And Clinics | Salt lake city, UT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| University Of Utah Specialty Services | 2961726831 | 75 |
News Archive
Raptor Pharmaceutical Corp., today announced that the first patient has been dosed in its Phase 2 clinical trial of DR Cysteamine for the potential treatment of Huntington's Disease. The Phase 2 clinical trial is being conducted under a previously announced collaboration agreement with The Centre Hospitalier Universitaire d'Angers ("CHU d'Angers"), which has commenced enrolling patients at eight clinical sites throughout France.
Follow-up results from two trials of the programmed death 1 receptor inhibitor nivolumab versus docetaxel in patients with advanced non-small cell lung cancer were reported at a proffered paper session held at the European Cancer Congress in Vienna, Austria.
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain today announced that it has received CE Mark approval (Conformite Europeenne) for the Zalviso device.
For individuals with a migrant background affected by dementia, access to medical information and care services can be hampered due to language barriers and cultural differences from the native population: This is because culturally sensitive medical and nursing care as well as multilingual information materials are not yet standard - neither in Germany nor in many other parts of Europe.
A new programme to strengthen the UK's position as a leader in the methods that underpin health research has been announced by the Medical Research Council and the National Institute for Health Research.
› Verified 9 days ago
| Entity Name | University Of Utah Specialty Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1043614811 PECOS PAC ID: 2961726831 Enrollment ID: O20150123002141 |
News Archive
Raptor Pharmaceutical Corp., today announced that the first patient has been dosed in its Phase 2 clinical trial of DR Cysteamine for the potential treatment of Huntington's Disease. The Phase 2 clinical trial is being conducted under a previously announced collaboration agreement with The Centre Hospitalier Universitaire d'Angers ("CHU d'Angers"), which has commenced enrolling patients at eight clinical sites throughout France.
Follow-up results from two trials of the programmed death 1 receptor inhibitor nivolumab versus docetaxel in patients with advanced non-small cell lung cancer were reported at a proffered paper session held at the European Cancer Congress in Vienna, Austria.
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain today announced that it has received CE Mark approval (Conformite Europeenne) for the Zalviso device.
For individuals with a migrant background affected by dementia, access to medical information and care services can be hampered due to language barriers and cultural differences from the native population: This is because culturally sensitive medical and nursing care as well as multilingual information materials are not yet standard - neither in Germany nor in many other parts of Europe.
A new programme to strengthen the UK's position as a leader in the methods that underpin health research has been announced by the Medical Research Council and the National Institute for Health Research.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jeffrey Paul Rosenbluth, MD Po Box 413032, Salt Lake City, UT 84141-3032 Ph: (801) 213-3900 | Jeffrey Paul Rosenbluth, MD 50 N Medical Dr, Salt Lake City, UT 84132-0001 Ph: (801) 581-2267 |
News Archive
Raptor Pharmaceutical Corp., today announced that the first patient has been dosed in its Phase 2 clinical trial of DR Cysteamine for the potential treatment of Huntington's Disease. The Phase 2 clinical trial is being conducted under a previously announced collaboration agreement with The Centre Hospitalier Universitaire d'Angers ("CHU d'Angers"), which has commenced enrolling patients at eight clinical sites throughout France.
Follow-up results from two trials of the programmed death 1 receptor inhibitor nivolumab versus docetaxel in patients with advanced non-small cell lung cancer were reported at a proffered paper session held at the European Cancer Congress in Vienna, Austria.
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain today announced that it has received CE Mark approval (Conformite Europeenne) for the Zalviso device.
For individuals with a migrant background affected by dementia, access to medical information and care services can be hampered due to language barriers and cultural differences from the native population: This is because culturally sensitive medical and nursing care as well as multilingual information materials are not yet standard - neither in Germany nor in many other parts of Europe.
A new programme to strengthen the UK's position as a leader in the methods that underpin health research has been announced by the Medical Research Council and the National Institute for Health Research.
› Verified 9 days ago
James Tran, MD Physical Medicine & Rehabilitation Medicare: Medicare Enrolled Practice Location: Rehab 85 N Medical Drive Rm 2122, Salt Lake City, UT 84132 Phone: 801-585-2589 | |
Dr. Chase K Hansen, DPT Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 1121 E Brickyard Rd Apt 1803, Salt Lake City, UT 84106 Phone: 801-309-0848 | |
Michael Tobler, Physical Medicine & Rehabilitation Medicare: Medicare Enrolled Practice Location: 6360 S 3000 E Ste 300, Salt Lake City, UT 84121 Phone: 385-900-5094 | |
Dr. Jeffrey G Randle, MD Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 1160 E 3900 S, #5000, Salt Lake City, UT 84124 Phone: 801-262-8486 Fax: 801-284-8699 | |
Dr. Michael Matthew Green, D.O. Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 81 N Mario Capecchi Dr, Department Of Pediatrics, Salt Lake City, UT 84113 Phone: 801-213-7737 Fax: 801-587-7539 | |
Ms. Allison Oki, M.D. Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 50 N Medical Dr, Univerisity Of Utah, Department Of Pm&r, Salt Lake City, UT 84132 Phone: 801-585-2589 Fax: 801-587-7287 | |
Bradeigh Smithson Godfrey, D.O. Physical Medicine & Rehabilitation Medicare: Medicare Enrolled Practice Location: 258 Heritage Ctr, Salt Lake City, UT 84112 Phone: 801-587-1290 |